Health Care & Life Sciences » Pharmaceuticals | Alfresa Holdings Corp.

Alfresa Holdings Corp. | Cash Flow

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
43,225
37,231
54,094
44,684
51,567
61,226
Depreciation, Depletion & Amortization
10,011
9,374
10,850
11,017
10,564
10,768
Other Funds
-
-
1,192
2,373
322
23,890
Funds from Operations
26,191
46,302
50,894
33,032
52,035
48,108
Changes in Working Capital
53,698
10,489
13,058
1,310
4,460
1,228
Net Operating Cash Flow
27,507
35,813
37,836
34,342
47,575
46,880
Capital Expenditures
20,899
15,889
14,243
13,686
12,482
Sale of Fixed Assets & Businesses
271
1,385
938
6,150
1,397
Purchase/Sale of Investments
1,093
10,381
5,396
896
849
Net Investing Cash Flow
21,769
6,583
15,245
13,409
10,154
Cash Dividends Paid - Total
5,312
6,118
7,094
7,367
8,233
Issuance/Reduction of Debt, Net
3,313
1,878
2,689
2,061
1,304
Net Financing Cash Flow
8,643
8,011
25,996
11,807
9,865
Net Change in Cash
57,850
21,262
3,422
9,094
27,571
Free Cash Flow
46,907
21,528
27,279
23,694
37,775
Net Assets from Acquisitions
-
2,433
7,004
6,597
-
Other Sources
313
256
201
442
337
Change in Capital Stock
18
15
15,021
5
4
Exchange Rate Effect
69
43
17
32
15
Other Uses
361
283
533
614
253

About Alfresa Holdings

View Profile
Address
Ote Center Building, 23/F
Tokyo Tokyo 100
Japan
Employees -
Website http://www.alfresa.com
Updated 07/08/2019
Alfresa Holdings Corp. engages in the management of its subsidiaries that deal with wholesaling, manufacturing, import, and export of pharmaceutical products, diagnostic reagents, and medical devices. It operates through the following segments: Ethical Pharmaceuticals Wholesaling, Self-Medication Products Wholesaling, Manufacturing, and Medical-related. The Ethical Pharmaceuticals Wholesaling segment provides wholesale prescription drugs, medical diagnostic reagents, medical devices, equipment, and materials to hospitals, clinics, dispensing pharmacies, and other institutions.